Search Results

AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.

Kraig Biocraft Laboratories, Inc., announces that it has achieved full capacity at its current production location. Hitting this milestone was part of Kraig Labs’ expansion plans for the first half of 2024.

Kraig Biocraft Laboratories, Inc., announces that it has expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid.

Kraig Biocraft Laboratories, Inc., announces that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids.

Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd., announced that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture industry, after successful first-year laboratory and greenhouse testing.

Kraig Biocraft Laboratories, Inc., announces that it has successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids.

Kraig Biocraft Laboratories, Inc., announces that production of its BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”) announces an update on the commercialization of its BAM-1 recombinant spider silk production hybrids.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has completed its analysis of its spring spider silk production trials

Kraig Biocraft Laboratories, Inc., announces that the spring production trials of the Company’s new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness.